Common Contracts

Contract

Clinical Trial Agreement • January 25th, 2018

• Contract Type
  Clinical Trial Agreement
• Filed
  January 25th, 2018

Clinical Trial Agreement SMLOUVA O KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení (“Smlouva”) je uzavírána mezi následujícími stranami: • Fakultní nemocnice Olomouc, having a place of business at I. P. Pavlova 185/6, Olomouc, zipcode 779 00, Czech Republic Identification number: 000 98 892, Tax identification number CZ000 98 892, represented by doc. MUDr. Roman Havlík, Ph.D., Director (the “Institution”), and • Fakultní nemocnice Olomouc, se sídlem na adrese I. P. Pavlova 185/6, Olomouc, PSČ 779 00, Česká republika, IČO: 000 98 892, DIČ: CZ000 98 892, zastoupená doc. MUDr. Romanem Havlíkem, Ph.D., ředitelem (“Zdravotnické zařízení”), a • Quintiles Czech Republic, s.r.o., having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ247 68 651 (“Quintiles”), and • Quintiles Czech Republic, s.r.o., s

Contract

Clinical Trial Agreement • May 25th, 2017

• Contract Type
  Clinical Trial Agreement
• Filed
  May 25th, 2017

CLINICAL TRIAL AGREEMENT The Clinical Trial Agreement (“Agreement”) is made by and between:  Krajská zdravotní a.s.,having a place of business at Sociální péče 3316/12A, 401 13 Ústí nad Labem, Czech Republic Identification number: 254 88 627, Tax identification number: CZ25488627, represented by Ing. Petr Fiala, managing director (the “Institution”), and  Quintiles Czech Republic, s.r.o.,having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: 247 68 651, Tax identificationnumber: CZ247 68 651 (“Quintiles”), and  Merck KGaA,having a place of business at Frankfurter Strasse 250, 64393 Darmstadt, Germany, Identification number: HRB 6164 (“Sponsor”) Each a “Party” and together the “Parties”. Protocol Number: EMR10070-005 A Phase III, open-label, multicenter trial of avelumab1 (MSB0010718C) versusProtocol Title: platinum-based doubletas a first-line treatment of recurrent or Stage IV PD-L1+ non-small cell lung ca

Contract

Clinical Trial Agreement • March 31st, 2017

• Contract Type
  Clinical Trial Agreement
• Filed
  March 31st, 2017

Clinical Trial Agreement The Clinical Trial Agreement (“Agreement”) is made by and between: • Krajská zdravotní, a.s., having a place of business at Sociální péče 3316/12A, 401 13 Ústí nad Labem, Czech Republic, Identification number: 254 88 627, Tax identification number: CZ25488627, represented by Ing. Petr Fiala, CEO (the “Institution”) (the “Institution”), and • Quintiles Czech Republic, s.r.o., having a place of business at Radlická 714/113a, zip code 158 00 Prague 5 - Jinonice, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ247 68 651 (“Quintiles”), and • Merck KGaA, having a place of business at Frankfurter Str. 250, Darmstadt, Germany, entered into the B Commercial Registry kept by the Common Court in Darmstadt under number HRB 6164 upon power of attorney represented by Quintiles Czech Republic,s.r.o. (“Sponsor”) Each a “Party” and together the “Parties.” Smlouva o klinickém hodnocení Tato smlouva o klinickém hodnocení („Smlouva”) je uzavírána m